In non-cancerous conditions, ANO1 contributes to the pathogenesis of asthma, cystic fibrosis, and hypertension by regulating ion homeostasis and membrane potential, positioning it as a promising therapeutic target. This evidence concerns the gene ANO1 and cystic fibrosis.